T. Man Pharmaceutical Public Company Limited, or TMAN, has announced a second-half strategy adjustment after sales through pharmacy channels, its main channel, were affected by a slowing market. This hit sales of own-brand products with high margins, while the OEM and DBU businesses continued to grow well but with lower margins, putting pressure on net profit. The company will accelerate its top five brands and new products in five disease areas where it has expertise, use incentive campaigns to motivate the sales team, and maintain growth in OEM, DBU, and e-commerce channels. For inorganic growth, it recently acquired the Lamoon Baby brand, which has operated for more than ten years, to expand into the family care market. It also plans to invest in additional production capacity for supplements to support the longevity product trend, and to push its propolis products toward becoming a global brand. It has already registered in South Korea and signed a cooperation agreement with a partner in Indonesia, with a launch expected in the second half of next year. In the China market, it is in talks to adjust contract terms with a new partner, and expects sales to gradually return in the second half through online and cross-border e-commerce channels. For pharmacy channels, it is beginning to see signs that spending is returning to normal in the third quarter of 2026, and will use a strategy of pushing products through the sales team together with marketing activities to stimulate sales.
T Man Pharmaceutical PCLStrategy to push high-margin own-brand products and new products in five disease areas aims to revive pharmacy sales, with signs of spending returning to normal in Q3 2026.
